Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Completed · Phase 3

Conditions studied: Venous Thrombosis

In brief

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).

Key facts

Study ID

NCT00440193

Run by

Bayer

People needed

3449

Starts

2007-03-01

Expected to finish

2010-04-01

Last updated by the study team

2014-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed acute symptomatic proximal DVT without symptomatic PE

You may not qualify if…

• Legal lower age limitations (country specific)
• Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
• Other indication for VKA than DVT and/or PE
• The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.

Where it is running

• Study site — Redlands, California, United States
• Study site — Bay Pines, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Idaho Falls, Idaho, United States
• Study site — Covington, Louisiana, United States
• Study site — Baltimore, Maryland, United States
• Study site — Boston, Massachusetts, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Greensboro, North Carolina, United States
• Study site — Greensboro, North Carolina, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Camp Hill, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Corsicana, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Murray, Utah, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Fredericksburg, Virginia, United States
• Study site — Spokane, Washington, United States
• Study site — Tacoma, Washington, United States
• Study site — Garran, Australian Capital Territory, Australia
• Study site — Darlinghurst, New South Wales, Australia
• Study site — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.